Cetuximab
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Trial Timeline
Sep 1, 2005 → Mar 1, 2006
NCT ID
NCT00207116About Cetuximab
Cetuximab is a phase 1 stage product being developed by Eli Lilly for Carcinoma, Non-Small-Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00207116. Target conditions include Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00698841 | Phase 2 | Completed |
| NCT00292955 | Phase 2 | UNKNOWN |
| NCT00362102 | Phase 2 | Completed |
| NCT00207116 | Phase 1 | Completed |
| NCT00082212 | Phase 2 | Terminated |
| NCT00162110 | Phase 2 | Completed |
| NCT00083720 | Phase 2 | Completed |
| NCT00207155 | Phase 1 | Completed |
| NCT00063388 | Phase 2 | Completed |
| NCT00055419 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung